anti-cancer treatment
[용어속성] Term
Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies
재활용된 COVID-19 약물과 폐암 약물 요법의 잠재적 약물 상호 작용
Review
[키워드] adverse outcomes
anti-cancer treatment
Azithromycin
cancer patient
Care
ceftriaxone
Chemotherapy
Chloroquine
Comorbidity
Complication
concomitant treatment
concomitant treatments
COVID-19
COVID-19 infection
COVID-19 pandemic
Dexamethasone
dissemination
drug
Drug interactions
drug-drug interaction
Drug-drug interactions
Famotidine
Favipiravir
Healthcare professional
healthcare professionals
history of smoking
Hydroxychloroquine
identification
identify
Immunosuppression
information
kinase inhibitors
Lopinavir
Lopinavir/ritonavir
lung cancer
lung cancer patient
lung cancer patients
malignancy
management
medication
medications
occur
oseltamivir
outcome
Patient
pharmacotherapy
Potential
Prophylactic
proportion
QT prolongation
rationale
receiving
recent
Remdesivir
reported
Reporting
Repurposed drug
ribavirin
risk
risk factor
Ritonavir
sarilumab
severity
smoking
Tocilizumab
tyrosine
tyrosine kinase inhibitors
umifenovir
with COVID-19
[DOI] 10.1016/j.arcmed.2020.11.006 PMC 바로가기 [Article Type] Review
[DOI] 10.1016/j.arcmed.2020.11.006 PMC 바로가기 [Article Type] Review
COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic
Review Article
[키워드] adverse outcome
adverse outcomes
age
anti-cancer treatment
association
Cancer
cancer patient
Care
caused
Chemotherapy
China
common
COVID-19
death
disease
Evidence
feature
First wave
identify
Immunotherapy
include
increased risk
indicated
Infection
International
lung cancer
Male sex
Mortality
MOST
National
number of comorbidity
oncology
outcome
pandemic
Patient
patients
Patients with cancer
performance status
predict
Probability
recent
recruitment
risk
risk factor
SACT
smoking
solid cancer
the SARS-CoV-2
the timing
therapy
trajectory
viral infection
[DOI] 10.1038/s41416-021-01324-x PMC 바로가기 [Article Type] Review Article
[DOI] 10.1038/s41416-021-01324-x PMC 바로가기 [Article Type] Review Article
Clinical Determinants Differentiating the Severity of SARS-CoV-2 Infection in Cancer Patients: Hospital Care or Home Recovery
Medicine
[키워드] Analysis
anti-cancer treatment
Antibody test
Asymptomatic
asymptomatic patient
baseline
Cancer
Cancer center
Cancer patients
Care
Chemotherapy
clinical
clinical factor
Community
composed
conducted
COVID-19
cumulative
Deceased
described
determinant
diagnosed
died
discharged patient
group
home
hospital
Hospital stay
Hospitalization
Hospitalized
hospitalized patient
hospitalized patients
Immunosuppression
intubation
median
median age
moderate
Mortality
MOST
New York City
older patient
outcome
Patient
patients who survived
performance status
positive
predict
previous study
receiving
required
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 RNA
survived
symptomatic
symptomatic patient
Symptoms
therapy
trajectory
Treatment
treatment of negative impact
virus
worse prognosis
[DOI] 10.3389/fmed.2021.604221 PMC 바로가기 [Article Type] Medicine
[DOI] 10.3389/fmed.2021.604221 PMC 바로가기 [Article Type] Medicine
Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection
Perspective
[키워드] adverse outcome
anti-cancer treatment
cancer patient
clinicians and researcher
Consequences
coronavirus
Course
COVID-19
COVID-19 patients
cytotoxic T lymphocyte antigen-4
evaluate the effect
Evidence
exacerbated
Hematological malignancies
Immune checkpoint inhibitor
Immune checkpoint inhibitors
immune response
immunosuppressive therapies
increased risk
Infection
infection with SARS-CoV-2
information
knowledge
less
management
morbidity and mortality
Mortality
pandemic
Patient
patients with COVID-19
programmed cell death protein
promote
receiving
risk
SARS-CoV-2
SARS-CoV2
SARS-CoV2 infection
Severe infection
Side effect
simple
solid cancer
T cell
Topic
treated
Treatment
turn
viral infection
with COVID-19
[DOI] 10.3390/cancers12113383 PMC 바로가기 [Article Type] Perspective
[DOI] 10.3390/cancers12113383 PMC 바로가기 [Article Type] Perspective
The Potential Role of Immune Alteration in the Cancer–COVID19 Equation—A Prospective Longitudinal Study
Article
[키워드] alteration
Analysis
anti-cancer treatment
Asymptomatic
Blood
Cancer
Cancer center
cancer patient
Cancer patients
cancer treatment
Cohort
collected
Course
COVID-19 infection
COVID19
Cytometry
demographic data
demonstrated
develop
enrolled
Evidence
expression
healthcare
healthcare worker
high-risk population
host response
IgA
IgG
IgM
Immune cell
Immune profile
immune response
immunological
Immunomodulatory agent
Immunomodulatory agents
Inconclusive
Infection
intravenous
lack
longitudinal
myeloid cell
oncology
pandemic
Patient
performed
Perspective
Potential
profile
Prospective
reduction
reduction in
reported
risk
role
SARS-CoV-2
SARS-CoV2
serology
simple
study period
surface markers
symptom severity
symptomatic case
treated
Treatment
was determined
were assessed
[DOI] 10.3390/cancers12092421 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/cancers12092421 PMC 바로가기 [Article Type] Article
COVID-19 in cancer patients: risk, clinical features, and management
암 환자의 COVID-19: 위험, 임상 특징 및 관리
Review
[키워드] 2019
acute respiratory syndrome
acute respiratory syndrome coronavirus
anti-cancer treatment
Anti-viral therapy
anticancer
biochemical
Cancer
cancer patient
Cancer patients
caused
Characteristics
clinical and biochemical characteristics
clinical care
Clinical features
Clinical management
coronavirus
coronavirus disease
COVID-19
COVID-19 infection
COVID-19 infections
Effect
effort
Health Organization
immunosuppressive
Immunotherapy
Inflammation
International
management
Novel coronavirus
outcome
Pathogenesis
Patient
patients
profiles
public health emergency
Research
respiratory
risk
SARS-CoV-2
SARS-COV-2 infection
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
severe COVID-19 symptoms
Spread
stimulate
therapy
Treatment
Treatment outcome
Tumor
tumor growth
vulnerable population
with COVID-19
World Health Organization
[DOI] 10.20892/j.issn.2095-3941.2020.0289 PMC 바로가기 [Article Type] Review
[DOI] 10.20892/j.issn.2095-3941.2020.0289 PMC 바로가기 [Article Type] Review
Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments
Review article
[키워드] anti-cancer treatment
anticancer
Cancer
caused
Chemotherapy
chemotherapy drugs
COVID-19
drug
drug interaction
General population
hepatic impairment
increased risk
Infection
Interaction
Patient
renal
reported
risk
SARS-CoV2
SARS-CoV2 infection
Treatment
treatments for COVID-19
[DOI] 10.1016/j.critrevonc.2020.102982 [Article Type] Review article
[DOI] 10.1016/j.critrevonc.2020.102982 [Article Type] Review article
Fertility Preservation in Cancer Patients During the Coronavirus (COVID-19) Pandemic
Oncology
[키워드] acute respiratory syndrome
affected
anti-cancer treatment
anti-cancer treatments
assist
Cancer patients
clinical care
condition
Corona virus
coronavirus
COVID-19
COVID-19 pandemic
disease
female patient
Fertility
fertility preservation
follicular
gonadotoxicity
growth
include
male
Oocyte
ovarian
pandemic
patients
Patients with cancer
preservation
produced
promote
recommendation
required
SARS-CoV-2
tissue
widespread
[DOI] 10.3389/fonc.2020.01009 PMC 바로가기 [Article Type] Oncology
[DOI] 10.3389/fonc.2020.01009 PMC 바로가기 [Article Type] Oncology
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
Research Article
[키워드] Abnormalities
Admission
age
Analysis
anti-cancer treatment
association
Breast cancer
breast cancer patient
breast cancer patients
Characteristics
clinical feature
Cohort
common
Comorbidities
Comorbidity
Corticosteroid
cough
COVID-19
COVID-19 complication
COVID-19 infection
COVID-19 mortality
COVID-19 patient
COVID-19 symptoms
cured
Curie
death
deaths
defined
diagnosed with COVID-19
Diagnosis
died
Factor
Fever
France
ground-glass opacity
higher risk
hospital
Hospitalized
hypertension
ICH
intensive care
lung CT scan
lung lesions
outcome
Paris
Patient
positive
radiation therapy
radiologic
radiological features
reported
Result
risk
RNA
SARS-CoV-2
severe COVID-19
survival
Symptom
transferred
treated
Treatment
Univariate analysis
Viral RNA
was done
with COVID-19
[DOI] 10.1186/s13058-020-01293-8 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1186/s13058-020-01293-8 PMC 바로가기 [Article Type] Research Article